- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| So | Corcept Therapeutics Incorporated: Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment | 613 | New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no... ► Artikel lesen | ||
| So | ESMO 2025: Faeth Therapeutics' Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy | 389 | Randomized phase 2 study in platinum-resistant ovarian cancer met its prespecified hazard ratio target and primary endpoint, supporting advancement to phase 3; combination extended mean progression-free... ► Artikel lesen | ||
| So | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | 415 | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | ||
| So | Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025 | 560 | TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients At data-cut-off on September... ► Artikel lesen | ||
| So | Gilead Sciences, Inc.: Trodelvy Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study | 562 | - Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine - - With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First... ► Artikel lesen | ||
| Sa | Daiichi Sankyo: ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial | 718 | More than 92% of patients treated with Daiichi Sankyo and AstraZeneca's ENHERTU were free of invasive disease at three years
DESTINY-Breast05 presented in ESMO Presidential Symposium I... ► Artikel lesen | ||
| Sa | Merck & Co., Inc.: KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery | 503 | First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer... ► Artikel lesen | ||
| Sa | AstraZeneca: ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial | 488 | Highest reported pathologic complete response rate seen in a Phase III registrational trial for HER2-positive early breast cancer with favorable safety profile vs. standard treatment DESTINY-Breast11... ► Artikel lesen | ||
| Sa | Merck & Co., Inc.: KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer | 586 | Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology... ► Artikel lesen | ||
| Sa | Bentley Systems, Incorporated: Bentley Systems gibt die Gewinner der Going Digital Awards 2025 bekannt | 416 | Das Unternehmen würdigt zudem wichtige Projekte mit den Founders' Honors, dem Bentley-Envision Award für nachhaltige Infrastruktur und dem Bentley Educator of the Year 2025. (Bentley Systems... ► Artikel lesen | ||
| Sa | Deciphera Pharmaceuticals Inc.: Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025 | 387 | - Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response -
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and... ► Artikel lesen | ||
| Sa | Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer | 491 | Updated data from the Phase 1/2 RAINFOL-01 trial showed rinatabart sesutecan (Rina-S) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR)... ► Artikel lesen | ||
| Sa | Salubris Biotherapeutics, Inc.: Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress | 372 | 5 confirmed partial responses (PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patients Favorable safety and PK profile, with... ► Artikel lesen | ||
| Sa | Kinaxis Inc.: Kinaxis beschleunigt mit der Einführung von Maestro Agents das Zeitalter der agentenbasierten Lieferkettenorchestrierung | 374 | KI-Agenten, die gemeinsam mit Ihnen planen und nicht nur für Sie, ermöglichen eine Kundenerfahrung der nächsten Generation der adaptiven Lieferkette Kinaxis® Inc. (TSX: KXS), ein weltweit führender... ► Artikel lesen | ||
| Sa | Genentech's Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer | 411 | - Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care... ► Artikel lesen | ||
| Sa | Kolibri Global Energy Inc. Provides Update Regarding Information Circular Disclosure | 323 | Kolibri Global Energy Inc. (the "Company" or "Kolibri") (TSX: KEI, NASDAQ: KGEI)wishes to provide an update to certain information contained in the management information circular and related materials... ► Artikel lesen | ||
| Sa | Qualcomm Incorporated: Qualcomm kündigt Quartalsdividenden-Ausschüttung an | 328 | Qualcomm Incorporated (NASDAQ: QCOM) gab heute eine Quartalsdividende in bar in Höhe von 0,89 US-Dollar je Stammaktie bekannt, zahlbar am 18. Dezember 2025 an die Aktionäre, die zum Geschäftsschluss... ► Artikel lesen | ||
| Sa | STEP Energy Services Ltd. Agrees to $5.50 Per Share Take Private Transaction With Funds Advised by ARC Financial Corp. | 101 | CALGARY, Alberta--(BUSINESS WIRE)--Further to its news release of September 25, 2025 announcing receipt of a non-binding offer from ARC Financial Corp., STEP Energy Services Ltd. ("STEP" or the "Company")... ► Artikel lesen | ||
| Fr | Illumynt berichtet über Geschäftsentwicklung im dritten Quartal 2025 | 235 | Das dritte Quartal 2025 war wieder ein ereignisreiches Quartal für uns bei Illumynt. Neben der Ernennung eines neuen Geschäftsführers haben wir einige Initiativen umgesetzt, die unsere Organisation... ► Artikel lesen | ||
| Fr | Eaton to announce third quarter 2025 earnings on November 4, 2025 | 262 | Intelligent power management company Eaton (NYSE:ETN) will announce third quarter 2025 earnings on Tuesday, November 4, 2025, before the opening of the New York Stock Exchange. The company will host... ► Artikel lesen | ||
| Fr | General Atomics Joins International Effort to Tackle One of Fusion's Biggest Hurdles and Unlock the Secrets of Fusion's Hottest Particles | 291 | Collaboration aims to boost efficiency and advance fusion power plant performance
Researchers at General Atomics (GA) are lending their expertise to address one of fusion energy's greatest challenges:... ► Artikel lesen | ||
| Fr | ProAmpac übernimmt den Geschäftsbereich Beutelverarbeitung von International Paper | 855 | ProAmpac, ein weltweit führendes Unternehmen im Bereich flexible Verpackungen und Materialwissenschaften, hat den Geschäftsbereich Beutelverarbeitung von International Paper ("IP"), einem weltweit... ► Artikel lesen | ||
| Fr | nVent Electric plc to Report Third Quarter 2025 Financial Results on October 31 | 244 | nVent Electric plc (NYSE: NVT) ("nVent"), a global leader in electrical connection and protection solutions, will report third quarter 2025 financial results on Friday, October 31, 2025.
The financial... ► Artikel lesen | ||
| Fr | Information Services Group, Inc.: Europa führt KI-gestützte Workday-Optimierung ein | 269 | Unternehmen integrieren KI-, Automatisierungs- und ESG-Tools, um ihre betriebliche Effizienz und Compliance zu verbessern, so der Bericht ISG Provider Lens
Europäische Unternehmen, die auf die... ► Artikel lesen | ||
| Fr | Avanzanite Bioscience B.V.: Avanzanite-Bioscience-Partner Agios gibt positive CHMP-Stellungnahme für PYRUKYND (Mitapivat) bei erwachsenen Patienten mit Thalassämie bekannt | 201 | Avanzanite ging im Juni 2025 eine exklusive Partnerschaft mit Agios zur Steuerung der Kommerzialisierung von PYRUKYND in Europa ein
Die Europäische Kommission wird die CHMP-Stellungnahme... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .